The FDA cleared a three-drug maintenance combination for HER2-positive breast cancer built around tucatinib

Tucatinib, trastuzumab and pertuzumab became an approved maintenance regimen on Oct. 7, 2026, when the Food and Drug Administration cleared the three drugs together for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. The patients covered are those who have already received induction therapy. Tucatinib, sold by Pfizer’s Seagen unit as Tukysa, is the drug added to the established antibody pair, and in the pivotal trial it stretched median progression-free survival from 16.3 months to 24.9 months.

The approval moves tucatinib out of the second-line setting it has occupied since 2020 and into the first line after induction, with a boxed warning for liver injury attached.

The Three Drugs and the Patients They Reach

The FDA’s approval notice names the regimen as tucatinib with trastuzumab and pertuzumab as maintenance treatment, with tucatinib dosed at 300 mg by mouth twice daily until the disease progresses or toxicity becomes unacceptable. Trastuzumab and pertuzumab are the antibody pair already standard in the first-line treatment of HER2-positive disease; tucatinib is an oral kinase inhibitor aimed at the same HER2 receptor from inside the cell. The notice leaves the dosing of the two antibodies to their own labels, and it states that Seagen Inc., a Pfizer subsidiary, is the applicant. Eligible patients in the trial could have brain metastases or not, a population the 2020 Tukysa indication also reached, and the notice states that overall survival was a secondary outcome.

The indication is tied to induction. In the trial, patients first received trastuzumab, pertuzumab and a taxane for four to eight cycles and had to be free of progression before randomization. Hamilton has described the regimen as a chemotherapy-free maintenance strategy, a label that applies only to the maintenance phase, since every participant had chemotherapy first.

HER2CLIMB-05 and the Progression-Free Survival Gain

The FDA grounded the approval in HER2CLIMB-05, a randomized, double-blind, placebo-controlled study of 654 adults, with or without brain metastases. According to Pfizer’s announcement, 326 patients received tucatinib with the two antibodies and 328 received placebo with them. Investigator-assessed median progression-free survival was 24.9 months against 16.3 months, a gap of 8.6 months, with a hazard ratio of 0.64 (95 percent confidence interval 0.51 to 0.80, p below 0.0001).

Overall survival, a secondary outcome, was not mature at the time of the progression-free survival analysis, so the label rests on a delay in progression and not on a demonstrated survival benefit. Erika Hamilton, the trial’s principal investigator at the Sarah Cannon Research Institute, said in the company release that “many patients still experience disease progression despite initial benefit from therapy.” The results appeared in the Journal of Clinical Oncology and were presented at the 2025 San Antonio Breast Cancer Symposium, Pfizer said.

Liver Toxicity and the Escalation Question

The label carries a boxed warning for hepatotoxicity, and warnings and precautions cover diarrhea, embryo-fetal toxicity and a rise in serum creatinine that does not reflect a change in kidney function. OncLive’s coverage reports grade 3 or higher adverse events in 42.3 percent of tucatinib patients versus 24.4 percent on placebo, elevated ALT at grade 3 or higher in 13.5 percent versus 0.6 percent, and discontinuation for adverse effects in 13.8 percent versus 4.6 percent.

Pfizer’s release adds that five confirmed Hy’s Law cases occurred, one of them fatal, all after rechallenge with the drug. Pharmaceutical Executive cites serious hepatotoxicity in 3.9 percent of patients and discontinuation for liver toxicity in 8 percent. Grade 3 or higher diarrhea ran 6.1 percent against 4.0 percent in the trial arms, according to OncLive. Pfizer’s release puts all-grade diarrhea at 73 percent of tucatinib-treated patients, with 6 percent at grade 3, and warns that it can cause dehydration, hypotension, acute kidney injury and death.

Ciara O’Sullivan, a Mayo Clinic oncologist quoted by OncLive, called the combination “an important escalation option after” induction with the taxane-and-antibody regimen, but cautioned that not every patient needs it. Some, she noted, do well for years on trastuzumab and pertuzumab alone, and better biomarkers are needed to identify who needs the more intensive therapy.

The 2020 Indication Tukysa Already Held

Tukysa was first approved in 2020 for use with trastuzumab and capecitabine in advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, after one or more prior anti-HER2 treatments. The Oct. 7 action adds a first-line maintenance use, as CancerNetwork’s report describes it.

Aamir Malik, Pfizer’s chief U.S. commercial officer, framed the decision as bringing the drug into the front-line maintenance setting. The unanswered clinical question is whether the 8.6-month progression-free gain translates into longer life. Overall survival is the measure, and the HER2CLIMB-05 investigators list it as a key secondary endpoint that had not matured when the FDA acted, so the answer is still to come from later analyses of the same 654 patients.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview